Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| ID | DOID:4829 |
| Name | adenosquamous lung carcinoma |
| Definition | An adenosquamous carcinoma located_in lung that derives_from lung tissue composed of at least 10% by volume each of squamous cell carcinoma (SqCC) and adenocarcinoma (AdC) cells. |
| Source | DiseaseOntology.org |
| Alt Ids | |
| Path | disease disease of cellular proliferation cancer organ system cancer respiratory system cancer lung cancer adenosquamous lung carcinoma |
| Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03894618 | Phase I | SL-279252 | SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas | Completed | USA | ESP | CAN | BEL | 0 |
| NCT04173507 | Phase II | Avelumab + Talazoparib | Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial) | Completed | USA | 0 |
| NCT04245514 | Phase II | Durvalumab | Multimodality Treatment in Stage III Non-small Cell Lung Cancer (NSCLC) | Active, not recruiting | DEU | CHE | 0 |
| NCT06225427 | Phase I | Gilteritinib | Gilteritinib for the Treatment of ALK NSCLC | Recruiting | USA | 0 |